# US 2026/0091085 A1 · Composition for systemic anticancer treatment in localized radiotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091085 A1
- Document ID: US20260091085A1
- Status: Published application
- Kind: A1
- Application number: 19/317,066
- Filed: 2025-09-02
- Published: 2026-04-02
- Earliest claimed: 2023-03-08
- Assignees: Inje University Industry-Academic Cooperation Foundation
- Applicants: Inje University Industry-Academic Cooperation Foundation
- Inventors: Sae Gwang PARK; Jin Hee PARK
- Web page: https://patentgrep.com/patent/US20260091085A1

## CPC

- A61K 38/215: {IFN-beta}
- A61K 38/21: Interferons {[IFN]}
- A61K 38/212: {IFN-alpha}
- A61K 38/217: {IFN-gamma}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61N 2005/1092: {Details}
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a composition for the prevention or treatment of metastatic cancer, capable of inducing an abscopal effect, which is a systemic anticancer effect, in combination with radiotherapy to treat metastatic cancer that has spread from a primary cancer, wherein, by having confirmed that, upon radiotherapy in which a primary cancer site was irradiated with a low dose of radiation, the abscopal effect, which is a systemic anticancer effect, did not appear, whereas, when type 1 interferon was administered in combination with low-dose radiation to the primary cancer site, an anticancer effect appears even in non-radiated metastatic cancer sites, a composition comprising type 1 interferon is provided as a therapeutic agent or adjuvant for the treatment of metastatic cancer, which induces a systemic anticancer effect upon low-dose radiotherapy.

## Claims

### Claim 1

A method of preventing or treating a metastatic cancer that is metastasized from a primary cancer in a subject in need thereof, comprising:
administering a pharmaceutical composition comprising a type 1 interferon as an active ingredient to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the type 1 interferon is IFN-α or IFN-β.

### Claim 3 (depends on 1)

The method of claim 1, wherein the type 1 interferon consists of an amino acid sequence represented by SEQ ID NO: 3.

### Claim 4 (depends on 1)

The method of claim 1, wherein the primary cancer is any one or more cancers selected from the group consisting of brain cancer, oral cancer, laryngeal cancer, pharyngeal cancer, stomach cancer, lymphoma, thyroid cancer, esophageal cancer, lung cancer, breast cancer, gallbladder cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, ovarian cancer, bladder cancer, cervical cancer, small intestine cancer, colon cancer, rectal cancer, colorectal cancer, bone cancer, skin cancer, endocrine cancer, and blood cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered after radiotherapy for cancer treatment.

### Claim 6 (depends on 5)

The method of claim 5, wherein the radiotherapy comprises localized irradiation of a primary cancer site with ablative or non-ablative low-dose radiation at a level of greater than 0 Gy and up to 6 Gy per fraction.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises an immune checkpoint inhibitor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the immune checkpoint inhibitor is one or more selected from the group consisting of anti-CTLA4 antibody, anti-PD-L1 antibody, and anti-PD-1 antibody.

### Claim 9

A method for enhancing an efficacy of radiotherapy for treatment a metastatic cancer that is metastasized from a primary cancer in a subject, comprising:
administering an adjuvant comprising a type 1 interferon as an active ingredient to the subject in conjunction with the radiotherapy.

### Claim 10 (depends on 9)

The method of claim 9, wherein the type 1 interferon is IFN-α or IFN-β.

### Claim 11 (depends on 9)

The method of claim 9, wherein the type 1 interferon consists of an amino acid sequence represented by SEQ ID NO: 3.

### Claim 12 (depends on 9)

The method of claim 9, wherein the radiotherapy comprises localized irradiation of a primary cancer site with ablative or non-ablative low-dose radiation at a level of greater than 0 Gy and up to 6 Gy per fraction.

### Claim 13 (depends on 9)

The method of claim 9, wherein the adjuvant is administered within one month immediately after the radiotherapy.

### Claim 14 (depends on 9)

The method of claim 9, wherein the primary cancer is any one or more cancers selected from the group consisting of brain cancer, oral cancer, laryngeal cancer, pharyngeal cancer, stomach cancer, lymphoma, thyroid cancer, esophageal cancer, lung cancer, breast cancer, gallbladder cancer, liver cancer, kidney cancer, pancreatic cancer, prostate cancer, ovarian cancer, bladder cancer, cervical cancer, small intestine cancer, colon cancer, rectal cancer, colorectal cancer, bone cancer, skin cancer, endocrine cancer, and blood cancer.

### Claim 15 (depends on 9)

The method of claim 9, wherein the adjuvant further comprises an immune checkpoint inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the immune checkpoint inhibitor is one or more selected from the group consisting of anti-CTLA4 antibody, anti-PD-L1 antibody, anti-PD-1, and anti-LAG-3 antibody.
